Moderna, Inc. (MRNA)
Moderna, Inc. (MRNA) is a Healthcare stock tracked by StreetAlpha. It last closed at $203.23 on Oct 5, up 7.08% on the day. MRNA reports earnings on Thu, Nov 5, 2026. The average 12-month price target from 8 analysts is $112.75 (-44.5% from the last close), with a high of $180.00 and a low of $77.00. Analyst consensus is Hold, based on the latest ratings from 8 firms (1 buy, 4 hold, 3 sell). Over the past 90 days StreetAlpha recorded 87 whale options trades in MRNA, 51% of them bullish and 49% bearish. In the past 30 days there were 66 dark pool prints totaling $89.6M, the largest $11.7M.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 8 analysts who set a price target on MRNA in the past 90 days. The average target is $112.75, with a high of $180.00 and a low of $77.00, compared with the last close of $203.23.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 30 | Citigroup | Downgrade | Sell | $60 → $80 |
| Sep 3 | Rothschild & Co | Downgrade | Sell | $81 |
| Aug 28 | Argus Research | Upgrade | Buy | $180 |
| Aug 24 | Barclays | Maintained | Hold | $125 |
| Aug 21 | JP Morgan | Maintained | Sell | $77 |
Whale Options Flow
90DDark Pool
30DFLEX Options Activity
FLEX Flow →FLEX options are customized, exchange-listed contracts used mostly by institutions. StreetAlpha scans the daily Cboe FLEX report for unusually large, long-dated positions. Multi-leg structures, such as paired calls and puts used for financing or hedging, are listed but not counted in these totals.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MRNA is in one of them and how their past MRNA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MRNA in an article yet. Here's the latest on the wider market.